Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre
Mandate

Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre

January 30, 2023 Employment and Benefits Commercial Agreements Intellectual Property M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data

Vendre is a provider of an innovative module-based eCommerce platform for customers in both B2B and B2C markets

Vendre AB was founded in 2007 and provides an innovative eCommerce platform with several different and unique functionalities to its over one hundred customers. Through the acquisition, Main Capital’s portfolio company Optimizers strengthens its product offering and position in the Nordic market, growing towards EUR 25 million in revenues and 170 employees.

Vinge’s team mainly consisted of Filip Öhrner, Olivia Belding, Nando Basic (M&A), Ebba Svenburg (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ellinore Boström Andersson (project assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025